Who is sponsoring NCT05576168?

NCT05576168 is sponsored by Shanghai 10th People's Hospital.

What drugs are being tested in NCT05576168?

Interventions in NCT05576168: overexpression STRA6/miRNA3.

What condition does NCT05576168 study?

NCT05576168 studies Beta Cell Dysfunction.

Is NCT05576168 still recruiting?

NCT05576168 is currently completed. Last updated 12 October 2022.

Last reviewed 2022-10-12 · How we verify

NCT05576168

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Related Mechanisms of RBP4 in Glycolipid Metabolism

Completed NA Last updated 12 October 2022

What this trial tests

NA trial testing overexpression STRA6/miRNA3 in Beta Cell Dysfunction in 200 participants. Completed in 1 July 2021.

Timeline

1 May 2018

Primary endpoint
1 June 2020

1 July 2021

Quick facts

Lead sponsor	Shanghai 10th People's Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 May 2018
Primary completion	1 June 2020
Estimated completion	1 July 2021
Sites	1 location across China

Drugs / interventions tested

overexpression STRA6/miRNA3 — full drug profile →

Conditions studied

Beta Cell Dysfunction — all drugs for Beta Cell Dysfunction →

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 18 to 60, any sex, with Beta Cell Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retinol binding protein 4 ( RBP4 ) is a newly discovered adipokine secreted by adipose tissue, which leads to insulin resistance ( IR ) and participates in the occurrence of T2DM. At present, it's not clear whether RBP4 can cause islet β cell dysfunction. The purpose of this study is to explore the role of serum apo-RBP4 in the pathogenesis of newly diagnosed T2DM patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
NCT07370441 — Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
NCT06783296 — Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension · NA · not yet recruiting
NCT07204496 — A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05576168 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai 10th People's Hospital
Last refreshed: 12 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05576168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing